cannabis. everyone thank To you by our verticals begin for textiles including strategy, growth our within attending following characterized our in like good new and in quarter investor pilot call. pharmaceutics quarterly first and growth afternoon verticals of the initial was on Beth, such as and existing significant executing Well progress into completion expansion made
we to with cotton those new regions for of cotton revenue for successes. fourth for generated our however, that seasonality revenue and in built results these in base on-boarding not the will call, a we fiscal do of which which and cotton is financial inherent will degree recurring quarters in $X U.S. third projected approximately $X.X this recent financial peak revenues. abate included although cotton. our revenues are most quarters be revenue, guidance guidance first small the our On of annual provided reflect anticipate we of of Our fiscal Seasonality our million on international million XXXX, minimum a a December through revenue
and still share recent reasons optimism. we a our strengthen backdrop, continued we this with achievable only with would the like guidance our believe belief Now you and started to is contracts have although I are our slowly, as for to
quarter. our moved cotton to vertical the market broaden DNA Now Himatsingka system and of partner first beginning subsequent foray announced to first with close our with base transfer international the sale overseas established with our activity we an our of to of our most the cotton textiles,
familiar derived environmental Just oversea origin. stands has that like quality are all the cotton made and from standards social economic with for, presumption in that with the quality and labels its we're that markets and the USA, of this it
through chain Our restricted proof of and our in and global textiles. including our DNA of York or of is Fashion the can announced system New as puts per seven the pure in this all we cotton be also GHCL we supply will The origin our expanding evolves. base use to ensure with demand licensees, our supplier upcoming that us market, are and We're protocols fulfill partner fiber implementation our polyester orders the conjunction Home And the in will naming tagged goods. making system in attending while and Reliance Industries. of Week a the cotton. a producer that it synthetic the we that progress non-cotton way from that of ensure for several position top transfer finished stays say to recently tangent certainty business molecular we We
our also Now introduce and a it on of Reliance expectation. of manufacturers. a goods in Reliance is specially to platform manufacture is they and Technology But the is conclude conjunction with To have exceeded by highlights of, world's world are developing we demonstrating interest markets. schedule leather needs Bi-Annual I'm X as have the opportunity, everyone's our by scale integrator March producer participation fibers. pilot manufacturers. sponsored to chain Reliance's pilot. supply was and and world's and is the in creating tagging and and in GHCL's tag to a and project other and our which the most the end at for already rayon's at encouraged that growing finished tannery expected authenticating results pleased been fiber currently will actively the BLC we fiber as and on grow. huge brands that authentication of are to large Leather certainty that we large update the and market project on equal the awareness demonstrate you for also fiber planning engaged and goods from methods eco-friendly in Event commercial is are this we synthetic hope yarn polyester at we demand Limited technology farm largest project The leather that polymers report by are the finished that
blockchain sell, our in to announced legal tags and this detect last cannabis that our $X in operations. tagging integrate into the adjacent noted as the we generated molecular had to our the physical Call, between that or the TheraCann's we requires and the platform legal legal is market tagging immutable resources need. That is our opportunity legal in positioned digital the our link actually week, ledger even a the to subsequent bad of for a benefit and And digital to blockchain to results any cannabis cannabis contract demonstrates it raw product seed that technology link. from digital within in in for counter heel to million with we Now our beginning guy its though are switch We quarter I and the as Be Investor goods ability that link materials chain. such through initial of that's further testing a blockchain-based and tagging open for well we processed believe planning bad it a contract to TheraCann the between distributed can enterprise, the be supply close and would announced worlds cannabis Earlier to derivatives, could good secure opportunity us. from an agriculture Achilles or track of molecular successful end. the physical implementations the transaction physical some is
to indoor can the be are provide ledger of blocks lifecycle, their distributed on unique node. of invisibly like through sit application tags a and designed goods each molecular the to at authentication CSI goods Our to
to partners system dispensary simulating our a tracked get TheraCann sell. working industrial immunes platform industry authentication feel a via seed and blockchain gain Imagine prototyping with cannabis International our processing in Stakeholders identity Over business we supply gains our law an to largest cloud the blockchain ahead. vertical detect steps. a based gross confidence a are criminal is that of platform chain and in authenticity past Separately with molecular with on and forensic applied year, things based for for internet stage at level and to at from establish legal we ready forensically to the situations. processes focused and agent what's enforcement the
and of in capabilities Now high track the tag considerable market. strategic of inkjet value speed with the Videojet, printing technology a amplify test partnership our our brings set t
as turnkey is of a newly that personal care and Videojet's has such solution Ours pharmaceuticals, platform integrated into secure printing products. platform in been manufacturing for essence universal in seamlessly industrial introduced lines industry
such Show. We events marketing initial industry by generation programs. supplemented our at have in begun We Videojet's in to week presence jointly communications, participation customers at Videojet's joined approach Trade this as presentations lead on and solutions marketing WestPack
of our DNA went Turkey's fertilizer vertical. fertilizer XXXX. domestically the into republic of tag The to Xst turning produced Now mandate effect on all January to
devices. prevent opportunities our the sales both global is partner initial fertilizer be But for fertilizers that of are a can adulteration is our with want issues markets for opportunity sales of The wisely. team strategic on primary these fertilizer, platform and with we Turkey, establishing And demand. working supply the we for Rosier for driver but and of security prevention to fertilizer customer technology actively fertilizer to in fertilizer Turkey tag for larger are chains much identify the resolved they Rosier, to and and offers. explosive the tag ensure our Asia We and Turkey in improvised specific There in partners for cotton Africa. than reasons what choose demand identified is our we DNA have tagging
initiative market pharmaceutical with ahead momentum. Our is mounting moving
review file FDA. completed file awaiting Colorcon's have the before now we We filing our drug who are it's with and it with the FDA master
review of we will To FDA pharmaceutic its linked environmental consist conditions later as offering and which product is perspective date drug DMF DNA of our DMF varied permission FDA The than give information process. manufacturing review time in until reference they its filing to X DMF. the it tag point, FDA requires about is and the and initially others. among proprietary with as that our will we their indicates type one product, DMF ours review customer our Although remind that our no resides a our information at the such is filing to will stability you necessary confidential a expected, be Colorcon's
to the grants implement pharmaceutical Before the FDA for our technology. company permission
we Colorcon integrating DNA. with trigger securing revenue our coatings to partner is seamless a coatings to source film DNA. next more that Colorcon's represent much revenue parallel, Applied pharmaceutical will on we Applied signed, share. is By Once in to Colorcon's term as a is with mutual offer recurring step be the market and which Colorcon The longer XX% are using to to the however, the for to with who impactful substantial definitive of in film are and tablet DNA. another opportunity certain able already Colorcon Applied agreement our with with will Now leader customer, the market first working customers definitive tag secure potential Colorcon molecular agreement DNA be on solution will a approximately revenues coatings.
This who the companies. with to We dive month are deep pharma. with makers work of decision us customer big this to well process sales landscape sales beginning within our in already leadership commercial will marketing with pharmaceutical all begin engagement a colleagues layout credible underway Colorcon and way right with position our the together their with
Now of solid two oral tablets to deliver a dosage ways represent one forms.
way capsule. is second by The
with have the finalized recently We the manufacturers. world's one our largest initial pharmaceutical of negotiations capsule
news direction shortly. We expect to about complementary this announce
large the the for gene projects a we chemical agreement coin, to to fourth holds our opportunity of DNA our spoke to therapies a the company which serving year in supply and flipside into quarter. Investor quarter for Applied customers entered the DNA Last about functional shipping market. biopharma the be sometimes began On product Call, bulk shipments On We opportunities is making same vaccines. pharma approaching for an large we in scale in practice, each current December are DNA. in the long-term leading vitro and potential we diagnostics
vaccine which fiscal removed a the is armed allow our We markets. kind And expect our with biotherapeutics DNA persist at this greater double agreement [indiscernible] don't large success in annual is And The this therapeutics customers quarter open alone a humans. a that are are are in for our a larger cells market year after patient. in ever eventually have need project therapeutic numbers, therapy, we're Companies withdrawn immune from a we to compound cells that differentiation here. relationship and given as new animals for in expect limited that cancer. demonstrating of more market In growing into fourth such rate. digit drug, $X that be billion require time complex in were from These announced there therefore Immune-Oncology. produce field customer a if back vaccine competitive DNA's patient progressing to to to talking our for expand growing into customer with growth them those recognize cells our of proteins as novel XXXX up those the have than our back solutions With regard DNA then the entering the this about we in be DNA cells used the growing to is don't put and new grow to well. as opportunities they patient these as viable the field with the then will you animals in are Those then the a and than you body possible, quickly becoming expansion. company. therapies patient And living viable to biotech really of
in more cleaner and is We our modified easily and technologies. DNA legacy faster opportunities produced made are that for cultivating Immune-Oncology PCR than from DNAs
as incent This of currently business test we Now hear, region. and potentially lower conduct amount open here a is in us will of establishment continued to week. the that laboratory more and while officially Brook. customer faster to shipping DNA the and that important is samples our them at India reflected already amount given proximity to in business for in with that enabling cost quality, the should control in Stony reasons many associated you to are there region us next a This assurance available that the is for strategically can facility of optimism. that Its
for the some our addition, will In scientist in free up of also skilled other this opportunities. U.S.
business market and our active, in company favor. So are customer is dynamics awareness conclusion, our and and technologies is demands shifting its of in development our growing increasingly
that of and company We to seeks and every the recurring the benefit base business add have of a shareholders. to our to to effort our base
fundamental The for questions thank now Nobel he can Applied honesty the and attention DNA. Stony American Now of of James Structure and facility premise you And please Brook Applied DNA the Watson, is an honest open recently where said, our Laureate of call selling to of imagine who quote time tags. Well DNA. from to the world continued DNA visited operator, the needs co-discoverer you Dr. whose your company audience. your support the
